Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Hemostemix ( (TSE:HEM) ) is now available.
Hemostemix has raised C$480,000 through a non-brokered private placement of 4,000,000 common shares priced at C$0.12 each, with the financing subject to final approval from the TSX Venture Exchange and subject to a statutory hold period under securities laws. The company intends to use the proceeds to fund general working capital and to advance regulatory, clinical and commercialization efforts for its ACP-01 (VesCell) autologous angiogenic cell therapy platform, supporting its push toward broader market adoption in ischemia-related indications and reinforcing its capital base for ongoing development initiatives.
The most recent analyst rating on (TSE:HEM) stock is a Hold with a C$0.08 price target. To see the full list of analyst forecasts on Hemostemix stock, see the TSE:HEM Stock Forecast page.
Spark’s Take on TSE:HEM Stock
According to Spark, TipRanks’ AI Analyst, TSE:HEM is a Neutral.
The score is primarily held down by very weak financial performance (no revenue, persistent losses, negative equity, and a sharp increase in recent cash burn), implying high reliance on external funding. Technicals are also weak-to-neutral with negative MACD and the price below key longer-term moving averages. Corporate events provide some support via incremental financing and product visibility, but not enough to offset the balance-sheet and cash-flow risks.
To see Spark’s full report on TSE:HEM stock, click here.
More about Hemostemix
Hemostemix Inc. is a Calgary-based autologous stem cell therapy platform company founded in 2003 that develops, patents, scales and sells VesCell (ACP-01), a blood-based angiogenic cell therapy. Focused on treating ischemic conditions such as peripheral arterial disease, chronic limb threatening ischemia, various forms of cardiomyopathy, congestive heart failure and angina, the company has completed seven clinical studies involving 318 subjects, published 11 peer-reviewed papers, and reported promising long-term outcomes from its Phase II trial in chronic limb threatening ischemia.
Average Trading Volume: 123,289
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$16.02M
For detailed information about HEM stock, go to TipRanks’ Stock Analysis page.